Novel anti-VEGF agent provides additional benefit when combined with ranibizumab for neovascular age-related macular degeneration | 2 Minute Medicine
2 Minute Medicine ,
1. In a phase 2 randomized trial, intravitreal injection with both ranibizumab and OPT-302, a VEGF-C and -D inhibitor, led to…